Pfizer Geodon Approved With Phase IV Sudden Death Study Commitment
• By Pharmaceutical Approvals Monthly
Pfizer will study sudden unexpected death occurring in patients taking Geodon (ziprasidone) and other atypical antipsychotics as a Phase IV commitment for the Feb. 5 approval of the oral schizophrenia drug.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
